BACKGROUND: The failure to increase CD4 T-cell counts in some HAART-treated HIV-infected patients with satisfactory virological responses has been related to low CD4 T-cell production, high turnover and death. However, the relative contribution of these factors is still unclear, strongly limiting the definition of appropriate therapeutic strategies for these patients. METHODS: A cross-sectional study was designed to evaluate the contribution of thymic activity, microbial translocation, cellular activation and death to CD4 T-cell recovery. We included 230 HIV-infected individuals on suppressive HAART (>2 years); 95 of them were considered 'discordant' (CD4 T-cell count <350 cells/mul) and 135 were considered 'concordant'. Comparative and logistic regression analyses were performed. RESULTS: Discordant patients showed higher levels of activated [human leukocyte antigen (HLA)-DRCD95 and CD38CD45RA] cells in both the CD8 and CD4 T-cell compartments. Notably, the most significant differences were observed in CD4 T cells. Discordant patients showed lower naive CD4 T-cell production (CD45RACD31 cells), higher spontaneous ex-vivo CD4 T-cell death and higher plasma levels of soluble CD14. Multivariate analysis showed that activation and death of CD4 T cells, along with nadir CD4 T-cell counts, were the only predictive factors for poor immune recovery. Moreover, the low correlations found between CD4 T-cell activation or death with thymic output and bacterial translocation suggest that additional factors modulate cellular activation and death and, in turn, CD4 T-cell recovery. CONCLUSION: CD4 T-cell repopulation during HAART is determined by CD4 T-cell activation and death. Therefore, strategies aimed to reduce these parameters should be envisaged to treat discordant patients.
BACKGROUND: The failure to increase CD4 T-cell counts in some HAART-treated HIV-infectedpatients with satisfactory virological responses has been related to low CD4 T-cell production, high turnover and death. However, the relative contribution of these factors is still unclear, strongly limiting the definition of appropriate therapeutic strategies for these patients. METHODS: A cross-sectional study was designed to evaluate the contribution of thymic activity, microbial translocation, cellular activation and death to CD4 T-cell recovery. We included 230 HIV-infected individuals on suppressive HAART (>2 years); 95 of them were considered 'discordant' (CD4 T-cell count <350 cells/mul) and 135 were considered 'concordant'. Comparative and logistic regression analyses were performed. RESULTS: Discordant patients showed higher levels of activated [human leukocyte antigen (HLA)-DRCD95 and CD38CD45RA] cells in both the CD8 and CD4 T-cell compartments. Notably, the most significant differences were observed in CD4 T cells. Discordant patients showed lower naive CD4 T-cell production (CD45RACD31 cells), higher spontaneous ex-vivo CD4 T-cell death and higher plasma levels of soluble CD14. Multivariate analysis showed that activation and death of CD4 T cells, along with nadir CD4 T-cell counts, were the only predictive factors for poor immune recovery. Moreover, the low correlations found between CD4 T-cell activation or death with thymic output and bacterial translocation suggest that additional factors modulate cellular activation and death and, in turn, CD4 T-cell recovery. CONCLUSION:CD4 T-cell repopulation during HAART is determined by CD4 T-cell activation and death. Therefore, strategies aimed to reduce these parameters should be envisaged to treat discordant patients.
Authors: Frank O Pettersen; Eirik A Torheim; Anders E A Dahm; Ingeborg S Aaberge; Andreas Lind; Malin Holm; Einar M Aandahl; Per M Sandset; Kjetil Taskén; Dag Kvale Journal: J Virol Date: 2011-04-13 Impact factor: 5.103
Authors: Linlin Li; Xutao Deng; Antonio Charlys Da Costa; Roberta Bruhn; Steven G Deeks; Eric Delwart Journal: J Clin Virol Date: 2015-10-08 Impact factor: 3.168
Authors: Timothy J Wilkin; Christina M Lalama; John McKinnon; Rajesh T Gandhi; Nina Lin; Alan Landay; Heather Ribaudo; Lawrence Fox; Judith S Currier; John W Mellors; Roy Gulick; Allan R Tenorio Journal: J Infect Dis Date: 2012-06-27 Impact factor: 5.226
Authors: Xinyan Zhang; Peter W Hunt; Scott M Hammer; Michelle S Cespedes; Kristine B Patterson; Ronald J Bosch Journal: HIV Clin Trials Date: 2013 Mar-Apr
Authors: Eugènia Negredo; Marta Massanella; Maria C Puertas; Maria J Buzón; Jordi Puig; Núria Pérez-Alvárez; Josué Pérez-Santiago; Anna Bonjoch; José Moltó; Antoni Jou; Patricia Echeverría; Josep M Llibre; Javier Martínez-Picado; Bonaventura Clotet; Julià Blanco Journal: J Antimicrob Chemother Date: 2013-05-14 Impact factor: 5.790